Search clinical trials for: Carboplatine

Total 3061 results

Tang-Du Hospital

Not yet recruiting

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Non-Small Cell Lung Cancer | Anti Angiogenesis

China
ARCAGY/ GINECO GROUP
Horizon 2020 - European Commission

Not yet recruiting

Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery (SALVOVAR)

Ovarian Cancer

France
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8
Beijing Chest Hospital, Capital Medical University

Not yet recruiting

Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC

Non Small Cell Lung Cancer

China
Swiss GO Trial Group
Tumor Profiler Center Switzerland

Not yet recruiting

OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy (OVPrecision)

Fallopian Tube Neoplasms | Ovarian Neoplasm Epithelial | High-grade Serous Ovarian Carcinoma (HGSOC) | Ovarian Endometrioid Carcinoma

Switzerland
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (DURVASCC)

Extrapulmonary Small Cell Carcinoma

Italy
Genelux Corporation
Newsoara Biopharma Co., Ltd.

Not yet recruiting

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25) ((VIRO-25))

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Advanced Non-squamous Non-small-cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Metastatic Squamous Non-Small Cell Lung Carcinoma | Non-small Cell Lung Cancer Recurrent | Metastatic Non-squamous Non Small Cell Lung Cancer and other conditions
Faeth Therapeutics
GOG Foundation

Not yet recruiting

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer

Endometrial Cancer
Zhou Chengzhi
Guangdong Provincial Hospital of Traditional Chinese Medicine; Sun Yat-sen... and other collaborators

Not yet recruiting

Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer
Lee's Pharmaceutical Limited

Not yet recruiting

Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer
Coherus Biosciences, Inc.

Not yet recruiting

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer (TRANSPARENT)

Nasopharyngeal Cancer Recurrent
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, China, Korea, Republic of, Belgium, Hong Kong, Japan, Taiwan, Denmark, Germany, Israel, Poland, Italy, United Kingdom, Bulgaria, Czechia, Portugal, Switzerland, Greece, Turkey, Romania, Sweden, France, Singapore, Mexico, ... and more
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal

Puerto Rico
AstraZeneca

Not yet recruiting

Volrustomig Priming Regimens Exploratory Phase II Platform Study (eVOLVE-01)

Non-small Cell Lung Cancer
The First Hospital of Jilin University

Not yet recruiting

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Platinum-sensitive Relapsed Ovarian Cancer
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR)

Not yet recruiting

Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes (OPTION-DDR)

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer
Anhui Provincial Cancer Hospital
Hutchison Medipharma Limited

Recruiting

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Ovarian Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Advanced Non-small Cell Lung Cancer
Fundación GECP

Not yet recruiting

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN)

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Resectable Lung Non-Small Cell Carcinoma

Spain
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First-line Advanced NSCLC Patients

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial Carcinoma | Recurrent or Metastatic | TP53 Mutation

China
Tel Aviv Medical Center

Not yet recruiting

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Triple Negative Breast Cancer
Sichuan University

Recruiting

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

Esophageal Cancer

China
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)

Neoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast Cancer

China
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Children's Oncology Group

Not yet recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor
Summit Therapeutics
Akeso

Recruiting

Phase III Study of AK112 for NSCLC Patients

Non-Squamous Non-small Cell Lung Cancer

Canada, United States, Spain, Italy, France, United Kingdom
Chinese PLA General Hospital

Recruiting

Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma

China
Centre Leon Berard
Groupe Français de Pneumo-Cancérologie

Not yet recruiting

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum (FIRST-NEC)

Large Cell Neuroendocrine Carcinoma of the Lung

France
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Beijing Chest Hospital, Capital Medical University

Not yet recruiting

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC (NeoSCLC-001)

Limited-stage Small-cell Lung Cancer
Fundacao Champalimaud

Not yet recruiting

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab (KEYPARTNER)

Triple Negative Breast Cancer | Early Breast Cancer

Portugal
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer Neck
Children's Oncology Group

Not yet recruiting

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Central Nervous System Germinoma | Diabetes Insipidus | Pineal Region Germinoma | Suprasellar Germinoma
University of Alabama at Birmingham

Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Non Small Cell Lung Cancer

United States
Zhongnan Hospital

Not yet recruiting

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Endometrial Neoplasms

China
Daiichi Sankyo
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Extensive Stage-small Cell Lung Cancer
The Affiliated Hospital of Qingdao University

Recruiting

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer (PILOT)

Non-small-cell Lung Cancer (NSCLC)

China
Université de Sherbrooke

Recruiting

Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma

Glioblastoma Multiforme | Relapse

Canada
Fudan University

Not yet recruiting

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
The Netherlands Cancer Institute
Merck Sharp & Dohme LLC

Not yet recruiting

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer (PRIAM)

Urologic Neoplasms | Urogenital Neoplasms | Penile Cancer | Male Urogenital Diseases | Penile Squamous Cell Carcinoma | Locally Advanced Penile Carcinoma
Fudan University

Not yet recruiting

Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Triple-negative Breast Cancer
Filipa Lynce, MD
Merck Sharp & Dohme LLC; Zentalis Pharmaceuticals

Recruiting

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Breast Cancer | Triple Negative Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor Negative Malignant Tumor Breast Triple

United States

Search clinical trials for: Carboplatine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations